ZA200901477B - Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors - Google Patents

Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors

Info

Publication number
ZA200901477B
ZA200901477B ZA200901477A ZA200901477A ZA200901477B ZA 200901477 B ZA200901477 B ZA 200901477B ZA 200901477 A ZA200901477 A ZA 200901477A ZA 200901477 A ZA200901477 A ZA 200901477A ZA 200901477 B ZA200901477 B ZA 200901477B
Authority
ZA
South Africa
Prior art keywords
pyrido
inhibitors
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
ZA200901477A
Other languages
English (en)
Inventor
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabeth Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200901477B publication Critical patent/ZA200901477B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
ZA200901477A 2006-09-15 2009-03-02 Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors ZA200901477B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
ZA200901477B true ZA200901477B (en) 2010-07-28

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200901477A ZA200901477B (en) 2006-09-15 2009-03-02 Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors

Country Status (42)

Country Link
US (3) US7696213B2 (fr)
EP (1) EP2074122B9 (fr)
JP (1) JP4718637B2 (fr)
KR (1) KR101099926B1 (fr)
CN (1) CN101573358B (fr)
AP (1) AP2710A (fr)
AR (1) AR062785A1 (fr)
AT (1) ATE514695T1 (fr)
AU (1) AU2007297212B8 (fr)
BR (1) BRPI0716749B8 (fr)
CA (1) CA2663401C (fr)
CL (1) CL2007002682A1 (fr)
CR (1) CR10662A (fr)
CU (1) CU23783B7 (fr)
CY (1) CY1111911T1 (fr)
DK (1) DK2074122T5 (fr)
DO (1) DOP2009000039A (fr)
EA (1) EA016388B1 (fr)
ES (1) ES2366489T3 (fr)
GE (1) GEP20115306B (fr)
GT (1) GT200700077A (fr)
HK (1) HK1138589A1 (fr)
HN (1) HN2007000267A (fr)
HR (1) HRP20110621T2 (fr)
IL (1) IL197243A (fr)
MA (1) MA30709B1 (fr)
ME (1) MEP8009A (fr)
MX (1) MX2009002927A (fr)
MY (1) MY146420A (fr)
NI (1) NI200900032A (fr)
NO (1) NO342357B1 (fr)
NZ (1) NZ575167A (fr)
PE (1) PE20080670A1 (fr)
PL (1) PL2074122T3 (fr)
PT (1) PT2074122E (fr)
RS (2) RS20090104A (fr)
SI (1) SI2074122T1 (fr)
TN (1) TN2009000085A1 (fr)
TW (1) TWI334353B (fr)
UY (1) UY30588A1 (fr)
WO (1) WO2008032162A1 (fr)
ZA (1) ZA200901477B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4718637B2 (ja) 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド(2,3−d)ピリミジノン化合物およびpi3阻害剤としてのその使用
EA020022B1 (ru) * 2007-04-10 2014-08-29 Экселиксис, Инк. Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
JP2010523681A (ja) * 2007-04-11 2010-07-15 エクセリクシス, インク. 癌の治療のためのPI3K−αの阻害剤としてのピリド[2,3−D]ピリミジン−7−オン化合物
MX336723B (es) * 2008-07-11 2016-01-28 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
CA2734489C (fr) 2008-08-20 2016-11-08 Southern Research Institute Derives de pyridine et de pyrimidine substitues par ethenyle et leur utilisation dans le traitement d'infections virales
EP2326627A1 (fr) 2008-08-20 2011-06-01 Schering Corporation Dérivés de pyridine et pyrimidine substituées et leur utilisation dans le traitement d'infections virales
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8101622B2 (en) * 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
SG190890A1 (en) 2010-12-16 2013-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
WO2013066483A1 (fr) 2011-08-31 2013-05-10 Novartis Ag Combinaisons synergiques d'inhibiteurs de pi3k et de mek
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
JP6631616B2 (ja) 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
KR20170058432A (ko) 2014-10-10 2017-05-26 화이자 인코포레이티드 상승 효과적 아우리스타틴 조합
SI3302565T1 (sl) 2015-06-04 2020-02-28 Pfizer Inc. Trdne farmacevtske oblike palbocikliba
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3481822B1 (fr) 2016-07-06 2022-06-22 The Regents of The University of Michigan Inhibiteurs multifonctionnels des voies biologiques de mek/pi3k et mtor/mek/pi3k et procédés thérapeutiques les utilisant
EP3497103B1 (fr) 2016-08-15 2021-05-05 Pfizer Inc. Inhibiteurs de pyridopyrimidinone cdk2/4/6
AU2017376766A1 (en) * 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
IL279329B1 (en) 2018-06-15 2024-09-01 Navitor Pharm Inc Rapamycin analogs and their uses
EP3902801A4 (fr) * 2018-12-28 2022-12-14 SPV Therapeutics Inc. Inhibiteurs de kinases cycline-dépendantes
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
WO2021139775A1 (fr) * 2020-01-10 2021-07-15 江苏先声药业有限公司 Composé de pyridone et son application
WO2022075974A1 (fr) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Inhibiteurs cycliques de trex1
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
CA3238551A1 (fr) * 2021-11-18 2023-05-25 Steven FRUCHTMAN Methodes et compositions pour traitement du cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
MD1861G2 (ro) 1994-11-14 2002-09-30 Уорнер-Ламберт Кампэни Derivaţi ai 6-arilpirido[2,3-d]pirimidinelor şi naftiridinelor, compoziţie farmaceutică pe baza lor, metode de tratament şi de inhibare a proliferării şi migraţiei celulei receptorului tirozinkinazei
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6-取代的吡唑并[3,4-d]嘧啶-4-酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
WO1998033798A2 (fr) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
SK10772002A3 (sk) 2000-01-27 2004-01-08 Warner-Lambert Company Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
EP1364950A4 (fr) 2001-02-26 2005-03-09 Tanabe Seiyaku Co Derive de pyridopyrimidine ou naphthyridine
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換6,6−ヘテロ二環式誘導体
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004089930A1 (fr) 2003-04-02 2004-10-21 Imclone Systems Incorporated Derives de 4- fluoroquinolone et leur utilisation comme inhibiteurs de kinase
WO2005040337A2 (fr) 2003-05-20 2005-05-06 The Regents Of The University Of California Procedes permettant de lier des agents a des plaques $g(b)-amyloides
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
US7326788B2 (en) 2003-07-22 2008-02-05 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CN1918158B (zh) 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2005082903A1 (fr) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2005094830A1 (fr) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinaisons d'inhibiteurs de transduction de signaux
WO2005105097A2 (fr) 2004-04-28 2005-11-10 Gpc Biotech Ag Derives de pyridopyrimidine
EP1749004B1 (fr) * 2004-05-04 2007-09-19 Warner-Lambert Company LLC Pyrid[2,3-d]pyrimidin-7-ones pyrrolyl-substituees et derives de ces dernieres utilises comme agents therapeutiques
EP1761281A1 (fr) 2004-06-04 2007-03-14 Pfizer Products Incorporated Methode de traitement de croissances cellulaires anormales
JP2008510770A (ja) 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Plk阻害剤としての新規プテリジノン
WO2006050501A2 (fr) 2004-11-03 2006-05-11 University Of Kansas Analogues de novobiocine en tant qu'agents anticancereux
CA2590294A1 (fr) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyridopyrimidinones, dihydropyrimidopyrimidinones et pteridinones utiles en tant qu'inhibiteurs des kinases raf
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
EP1940839B1 (fr) * 2005-10-07 2013-07-31 Exelixis, Inc. INHIBITEURS DE PI3Kalpha DE TYPE PYRIDOPYRIMIDINONE
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
EP1872922A1 (fr) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Procédé et dispositif de fabrication d'un article en matière plastique
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
JP4718637B2 (ja) 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド(2,3−d)ピリミジノン化合物およびpi3阻害剤としてのその使用
BRPI0808772A2 (pt) * 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog
JP2010523681A (ja) 2007-04-11 2010-07-15 エクセリクシス, インク. 癌の治療のためのPI3K−αの阻害剤としてのピリド[2,3−D]ピリミジン−7−オン化合物
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
CN102970868A (zh) * 2010-04-16 2013-03-13 柯瑞斯公司 具有k-ras突变的癌症的治疗

Also Published As

Publication number Publication date
PT2074122E (pt) 2011-08-24
SI2074122T1 (sl) 2011-10-28
EP2074122B1 (fr) 2011-06-29
HN2007000267A (es) 2011-02-25
AR062785A1 (es) 2008-12-03
UY30588A1 (es) 2008-05-02
AP2710A (en) 2013-07-30
HRP20110621T1 (en) 2011-09-30
IL197243A (en) 2013-07-31
IL197243A0 (en) 2009-12-24
CA2663401A1 (fr) 2008-03-20
BRPI0716749A2 (pt) 2014-02-18
US7696213B2 (en) 2010-04-13
KR20090040389A (ko) 2009-04-23
HRP20110621T2 (hr) 2013-12-06
TW200820972A (en) 2008-05-16
RS51927B (en) 2012-02-29
NO20091141L (no) 2009-03-31
MX2009002927A (es) 2009-03-31
MEP8009A (en) 2011-12-20
CN101573358B (zh) 2012-05-30
US8633204B2 (en) 2014-01-21
BRPI0716749B8 (pt) 2021-05-25
NZ575167A (en) 2010-10-29
KR101099926B1 (ko) 2011-12-28
AU2007297212B8 (en) 2011-04-28
CN101573358A (zh) 2009-11-04
BRPI0716749B1 (pt) 2020-10-06
US20080090801A1 (en) 2008-04-17
EP2074122B9 (fr) 2013-09-11
EP2074122A1 (fr) 2009-07-01
AU2007297212A1 (en) 2008-03-20
AU2007297212B2 (en) 2011-04-14
PE20080670A1 (es) 2008-06-14
ATE514695T1 (de) 2011-07-15
US20100137279A1 (en) 2010-06-03
GT200700077A (es) 2009-08-03
WO2008032162A8 (fr) 2009-03-26
US8273755B2 (en) 2012-09-25
DK2074122T5 (da) 2014-03-17
GEP20115306B (fr) 2011-10-10
RS20090104A (en) 2010-06-30
DOP2009000039A (es) 2015-12-15
JP4718637B2 (ja) 2011-07-06
MY146420A (en) 2012-08-15
US20120309775A1 (en) 2012-12-06
EA200970207A1 (ru) 2009-08-28
CU20090040A7 (es) 2011-07-11
JP2010503653A (ja) 2010-02-04
CU23783B7 (es) 2012-02-15
ES2366489T3 (es) 2011-10-20
CY1111911T1 (el) 2015-11-04
TN2009000085A1 (fr) 2010-08-19
ES2366489T9 (es) 2013-12-27
WO2008032162A1 (fr) 2008-03-20
AP2009004790A0 (en) 2009-04-30
MA30709B1 (fr) 2009-09-01
DK2074122T3 (da) 2011-08-15
EA016388B1 (ru) 2012-04-30
CR10662A (es) 2009-04-17
HK1138589A1 (en) 2010-08-27
CL2007002682A1 (es) 2008-04-04
NO342357B1 (no) 2018-05-14
TWI334353B (en) 2010-12-11
CA2663401C (fr) 2011-07-12
NI200900032A (es) 2010-05-14
PL2074122T3 (pl) 2011-10-31

Similar Documents

Publication Publication Date Title
ZA200901477B (en) Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors
IL210821A0 (en) Pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
IL198509A0 (en) Azaindole derivatives, compositions containing the same and uses thereof
IL201836A0 (en) Pyrrolopyridine derivatives and their use as bace inhibitors
ZA201004524B (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
PL2004654T3 (pl) Pochodne pirazolopirymidyny do stosowania jako antagonisty kinazy
EP1993539A4 (fr) Thiazolones utilisés en tant qu'inhibiteurs de p13-kinases
HK1128471A1 (en) Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
IL197231A0 (en) Pyrimidines derivatives and their use as kinase inhibitors
IL210822A0 (en) Tri-cyclic pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
IL198250A0 (en) Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
SI1888580T1 (sl) Pirido d pirimidini uporabni kot inhibitorjiHCV in postopki za njihovo pripravo
EP2217590A4 (fr) Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kinase p13
EP1993535A4 (fr) Thiazolones utilisés en tant qu'inhibiteurs de p13-kinases
EP2061470A4 (fr) Dérivés de la pyrimidinone substitués par un halogénoalkyle
ZA201101861B (en) Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
SI2004654T1 (sl) Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
EP1993536A4 (fr) Thiazolones utilisés en tant qu'inhibiteurs de p13-kinases
EP1993537A4 (fr) Thiazolones utilisés en tant qu'inhibiteurs de p13-kinases
EP1996191A4 (fr) Thiazolones utilisés en tant qu'inhibiteurs de p13-kinases
IL212736A0 (en) Pharmaceutical combinations comprising a pyrido [4,3-d] pyrimidine derived hsp90-inhibitor and a her2 inhibitor
EP1993538A4 (fr) Thiazolones utilisés en tant qu'inhibiteurs de p13-kinases